The ongoing CONFIDENCE trial (NCT05254002) is designed to prospectively assess the albuminuria-lowering effects of monotherapy with the SGLT2 inhibitor empagliflozin, finerenone and their combination in 807 adults with T2D and CKD [46]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.